Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. The company's lead candidate, JADE101, targets the cytokine APRIL and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody candidate, both in preclinical development. The company was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Industry
Biotechnology
Remote Policy
Fully Remote
Beta · Sourced from candidate reports
Be the first to share your experience with Jade Biosciences, Inc..
Your reply helps other candidates know what to expect.
